HIV, Subclinical Cardiovascular Disease, and Clinical Progression Insights From Immunologic Heterogeneity

Matthew J. Feinstein

doi:10.1001/JAMA.2022.15226

HIV, Subclinical Cardiovascular Disease, and Clinical Progression Insights From Immunologic Heterogeneity

Matthew J. Feinstein^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Editorial › peer-review

10 Scopus citations

Original language	English (US)
Pages (from-to)	931-932
Number of pages	2
Journal	JAMA
Volume	328
Issue number	10
DOIs	https://doi.org/10.1001/JAMA.2022.15226
State	Published - Sep 13 2022

Funding

reported receiving grants from the National Institutes of Health, National Heart, Lung, and Blood Institute (R01HL154862 and R01HL156792) and serving on the advisory board of Novartis AG outside the submitted work.

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1001/JAMA.2022.15226

Cite this

@article{41e94ef2eda4414ca6830d9ddcafafe9,

title = "HIV, Subclinical Cardiovascular Disease, and Clinical Progression Insights From Immunologic Heterogeneity",

author = "Feinstein, {Matthew J.}",

note = "Funding Information: reported receiving grants from the National Institutes of Health, National Heart, Lung, and Blood Institute (R01HL154862 and R01HL156792) and serving on the advisory board of Novartis AG outside the submitted work.",

year = "2022",

month = sep,

day = "13",

doi = "10.1001/JAMA.2022.15226",

language = "English (US)",

volume = "328",

pages = "931--932",

journal = "JAMA",

issn = "0098-7484",

publisher = "American Medical Association",

number = "10",

}

TY - JOUR

T1 - HIV, Subclinical Cardiovascular Disease, and Clinical Progression Insights From Immunologic Heterogeneity

AU - Feinstein, Matthew J.

N1 - Funding Information: reported receiving grants from the National Institutes of Health, National Heart, Lung, and Blood Institute (R01HL154862 and R01HL156792) and serving on the advisory board of Novartis AG outside the submitted work.

PY - 2022/9/13

Y1 - 2022/9/13

UR - http://www.scopus.com/inward/record.url?scp=85138448303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138448303&partnerID=8YFLogxK

U2 - 10.1001/JAMA.2022.15226

DO - 10.1001/JAMA.2022.15226

M3 - Editorial

C2 - 36098735

AN - SCOPUS:85138448303

SN - 0098-7484

VL - 328

SP - 931

EP - 932

JO - JAMA

JF - JAMA

IS - 10

ER -

HIV, Subclinical Cardiovascular Disease, and Clinical Progression Insights From Immunologic Heterogeneity

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this